Patents Examined by Constantina E Stavrou
  • Patent number: 12655394
    Abstract: The present invention relates to a method for the production of a culture, e.g. an organoid culture of ovarian cancer or cancer precursor cells, particularly of high grade serous ovarian carcinoma cells. By means of this method, an organoid culture of ovarian cancer or cancer precursor cells and a biobank comprising a plurality of different organoid cultures of ovarian cancer or cancer precursor cells may be generated. Further, a culture medium suitable for the long-term culture of ovarian cancer or cancer precursor cells is provided. Furthermore, use of the organoid culture and the biobank for medical applications, e.g. in the field of diagnostics, and therapy and in the field of drug screening is described.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 16, 2026
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FĂ–RDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Thomas F. Meyer, Mirjana Kessler
  • Patent number: 12624339
    Abstract: A brain organoid containing optic vesicles generated based on H9 induction and an eye-brain fusion culture method thereof are provided. H9 embryonic stem cell induction is used to generate a brain organoid containing optic vesicles with primitive visual field. Based on an established optic vesicle brain organoid culture system, microscopic imaging is combined with specific marker antibodies related to early retinal development and photoreceptor cell maturation to structurally and functionally identify the brain organoid containing optic vesicles.
    Type: Grant
    Filed: June 4, 2025
    Date of Patent: May 12, 2026
    Assignee: Tianjin University
    Inventors: Liqun Chen, Rui Hu, Dong Ming
  • Patent number: 12624368
    Abstract: Disclosed are delivery and expression systems of multiple antiviral therapeutic molecules. The therapeutic molecules include a novel class of dual-functional peptide and defective interfering genes of a virus. Also disclosed are compositions comprising the therapeutic molecules that are useful for the treatment and prevention of viral infections. Also disclosed herein are the method of making and using a vector that expresses the therapeutic molecules. Therapeutic molecules include cellular components such as RNA, DNA, peptide, proteins or combination thereof.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 12, 2026
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Hanjun Zhao, Kai Wang Kelvin To, Kwok Yung Yuen
  • Patent number: 12577530
    Abstract: Provided herein are methods of generating hindbrain cells, including respiratory hindbrain cells, from pluripotent stem cells. Also provided are methods of generating a three-dimensional organoid comprising a population of hindbrain cells including a heterogeneous population of interneurons.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: March 17, 2026
    Assignees: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, The Regents of the University of California
    Inventors: Jessica C. Butts, Todd C. McDevitt
  • Patent number: 12551506
    Abstract: Provided herein are, in various embodiments, methods and compositions for differentiating olfactory mucosa-derived mesenchymal stem cells (OM-MSC). In certain embodiments, the disclosure provides for media to differentiate OM-MSCs. In still further embodiments, the disclosure provides for methods and compositions using differentiated OM-MSCs for the treatment of nerve repair. In particular embodiments, the disclosure provides for novel treatments of peripheral nerve repair.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: February 17, 2026
    Assignee: NORTHEASTERN UNIVERSITY
    Inventors: Ryan A. Koppes, Katelyn E. Neuman, Abigail N. Koppes, Aidan Kenny
  • Patent number: 12550886
    Abstract: A method for human sperm vitrification is disclosed, which includes providing liquefied human sperm; having a vitrification medium, where the vitrification medium has (a) a sperm buffer, and (b) a cryoprotectant mixture including a permeable cryoprotectant and a non-permeable cryoprotectant; mixing the liquefied sperm with the vitrification medium; providing a sperm straw and loading the straw with 0.25 to 0.5 mL of the obtained mixture; sealing the straw with heat; and placing the straw vertically in a container with liquid nitrogen to vitrify the mixture. A portable kit is also disclosed, which makes it easy to implement the method. The kit includes a vitrification medium, some straws, a container, usage instructions, among others.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: February 17, 2026
    Assignee: UNIVERSIDAD DE LA FRONTERA
    Inventors: Raul Segundo Sanchez Gutierrez, Mabel Andrea Schulz Rubilar, Juan Jesus Alvarez Gonzalez, Albert Obradors Cherta, Enrique Oquinena Muguerza
  • Patent number: 12551574
    Abstract: Provided are recombinant nucleic acids (e.g., vectors), and related methods, for expression of a target gene in a host cell. The recombinant nucleic acids comprise a promoter comprising a nucleic acid sequence having at least 70% sequence identity to a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9; a cloning site for insertion of a nucleic acid encoding the target gene; and at least one non-promoter regulatory element required for the expression of the target gene in the host cell.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: February 17, 2026
    Assignee: The Trustees of Princeton University
    Inventors: Esteban Engel, Carola Maturana, Lynn Enquist
  • Patent number: 12516293
    Abstract: Methods for expanding beating cardiomyocytes, comprising treating the beating cardiomyocytes with one or more Wnt agonists, one or more bioactive lipids or a combination of one or more Wnt agonists and one or more bioactive lipids. Methods for differentiating stem cells, including iPS cells, into beating cardiomyocytes, comprising treating the iPS cells with a combination of one or more Wnt agonists and one or more bioactive lipids. Compositions and kits for regenerative medicine, comprising beating cardiomyocytes, one or more Wnt agonists and one or more bioactive lipids.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 6, 2026
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Sean M. Wu, Jan W. Buikema, Arun Sharma
  • Patent number: 12507679
    Abstract: Descried in certain example embodiments herein are engineered fish, particularly engineered catfish, that are engineered to contain modified myostatin, melanocortin-4 receptor, and/or one or more n-3 fatty acid biosynthesis pathway genes and/or gene products.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: December 30, 2025
    Assignee: AUBURN UNIVERSITY
    Inventors: Rex A. Dunham, Michael Coogan, Roger Cone, Veronica Alston
  • Patent number: 12497591
    Abstract: The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 16, 2025
    Assignees: Sorbonne Universite, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sacha Reichman, Olivier Goureau, José-Alain Sahel
  • Patent number: 12492378
    Abstract: Provided is a method of producing a somite cell from a pluripotent stem cell, comprising the step of culturing a pluripotent stem cell in a medium comprising a GSK3? inhibitor. Provided is a method of producing a dermatome cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising a GSK3? inhibitor and BMP. Provided is a method of producing a syndetome cell from a sclerotome cell, comprising the steps of culturing a sclerotome cell in a medium comprising FGF and then culturing the cell in a medium comprising BMP and TGF?. Provided is a method of producing a mesenchymal stromal cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising FGF. Provided are methods of producing a myotome cell, a dermatome cell, a sclerotome cell, and a syndetome cell from a pluripotent stem cell through a somite cell by appropriately combining the above methods and known methods.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: December 9, 2025
    Assignee: Kyoto University
    Inventors: Makoto Ikeya, Taiki Nakajima
  • Patent number: 12467033
    Abstract: The present invention provides methods and systems for enhanced production and/or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing various shear stress conditions on a variety of stem cells.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: November 11, 2025
    Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED
    Inventors: Shulamit Levenberg, Shaowei Guo, Barak Zohar
  • Patent number: 12459983
    Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, that exhibit cross-talk between the receptors.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: November 4, 2025
    Assignee: A2 BIOTHERAPEUTICS, INC.
    Inventor: Alexander Kamb
  • Patent number: 12405265
    Abstract: Provided herein are compositions and methods for real-time identification and isolation of base-edited cell populations. Also provided herein are methods for producing enriched isogenic lines of genetically modified cells, including base-edited human pluripotent stem cells. In particular, provided herein are methods utilizing transient expression of reporter proteins, the detectable signal of which is altered following base editing. Using the transient reporter with a base editor permits enrichment of isogenic populations of base-edited cells.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: September 2, 2025
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: David Brafman, Xiao Wang, Nicholas Brookhouser, Stefan Tekel, Kylie Standage-Beier
  • Patent number: 12404306
    Abstract: Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: September 2, 2025
    Assignee: Precigen, Inc.
    Inventors: Douglas E. Brough, Cheryl G. Bolinger, Ramya Yarlagadda, Vinodhbabu Kurella, Prabakaran Ponraj, Simon Metenou, Kuan-Fu Ding
  • Patent number: 12351605
    Abstract: The present invention relates to the field of stem cells. More specifically, the present invention provides compositions and methods for using optogenetics to sustain the pluripotency of stem cells. In one embodiment, a vector comprises a nucleotide sequencing encoding a fusion protein comprising the intracellular domain of fibroblast growth factor 1 receptor (FGFR1) and a photoactivatable domain.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: July 8, 2025
    Assignee: The Johns Hopkins University
    Inventors: Gabsang Lee, Hyesoo Kim, InYoung Choi, HoTae Lim, Alex V. Huynh
  • Patent number: 12264190
    Abstract: This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: April 1, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Gordon Moody, Maria Letizia Giardino Torchia, Michael Glen Overstreet, Ryan Gilbreth
  • Patent number: 12234478
    Abstract: The present invention relates to a method for the preparation of autologous human primary hair follicles in 3D cultures, comprising the isolation of primary fetal follicles; isolation of the patient's hair follicle cells; isolation of skin cells of the patient's scalp; extraction of growth factors from fetal follicle cells; the fibrin gel creation that contains growth factors of fetal follicles; sandwich cultivation of patient's hair follicle cells and skin of the patients scalp on or into fibrin gel that contains growth factors of fetal follicles; separation from fibrin gel the patients primary hair follicles, which can be used to treat baldness as an autologous graft.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 25, 2025
    Assignee: REELABS PVT. LTD.
    Inventors: Abhijit Bopardikar, Oleksandr Kukharchuk, Padma Priya Anand Baskaran, Andrii Kukharchuk, Sunil Pophale, Rohit R. Kulkarni
  • Patent number: 12221469
    Abstract: The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: February 11, 2025
    Assignees: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John Connolly, Sean Parker, Kenan Christopher Garcia
  • Patent number: 12173325
    Abstract: The present invention relates to a method for fabrication of a three-dimensional lung organoid comprising human stem cell-derived alveolar macrophages. Specifically, a lung organoid is fabricated by co-culturing cells not expressing the definitive endoderm marker CRCX4 according to a fabrication method of the present disclosure. The lung organoid comprises type 1 and type 2 alveolar epithelial cells as well as alveolar macrophages and realizes infectious or inflammatory responses unlike conventional lung organoids that contain no immune cells and as such, can be advantageously used in studying mechanisms of related lung diseases, excavating biomarkers, developing therapeutic agents, and so on.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 24, 2024
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Eun-Mi Kim, Ki-Suk Kim, Hyang-Ae Lee